GCP
GILD icon

Gill Capital Partners’s Gilead Sciences GILD Stock Holding History

Gill Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-338
Closed -$42.7K – 338
2026
Q2 		$42.7K Hold
338
– – 0.01% 291
2026
Q1 		$47.1K Buy
+338
New +$47.3K 0.01% 267

Other funds holding GILD

CIM
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
B
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.32B AUM 21.6% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
AF
Avanza Fonder Stockholm, Sweden $5.23B AUM 33.79% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.66B AUM 29.77% 1-Year Est. Return

Gill Capital Partners's GILD Position: Q3 2026 in Review

Gill Capital Partners sold out of Gilead Sciences (GILD) in Q3 2026, closing a stake of 338 shares — an estimated $42.7K sold.

Gill Capital Partners first reported a position in GILD in Q1 2026 and held it in 2 quarters. The position peaked at $47.1K in Q1 2026. 189 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Gill Capital Partners reported no remaining Gilead Sciences position as of Q3 2026 after selling out during the quarter.
  • Gill Capital Partners sold 338 Gilead Sciences shares in Q3 2026, an estimated $42.7K.
  • Gill Capital Partners first reported a position in Gilead Sciences in Q1 2026 and held it in 2 quarters.
  • Gill Capital Partners's Gilead Sciences position peaked at $47.1K in Q1 2026.
  • 189 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Gill Capital Partners's 13F filing for Q3 2026, filed 13 Oct 2026.